Erratum: Neuroendocrine cancer-are two radionuclides better than one (Nature Reviews Endocrinology (2012) 8 (326-328) DOI: 10.1038/nrendo.2012.64);Therapy: Neuroendocrine cancer-are two radionuclides better than one?

Nature Reviews Endocrinology

Volumn 8, Issue 6, 2012, Pages 326-328

  Kwekkeboom, Dik J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

LUTETIUM 177; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; SUNITINIB; YTTRIUM 90;

CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARCINOID; CLINICAL STUDY; HUMAN; ISOTOPE LABELING; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; PANCREATIC NEUROENDOCRINE TUMOR; PEPTIDE RECEPTOR RADIONUCLIDE THERAPY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RADIATION DOSE; SHORT SURVEY;

EID: 84861337015     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2012.130     Document Type: Erratum

References (10)

1. Villard, L. et al. Cohort study of somatostatin-based radiopeptide therapy with [90Y-DOTA]-TOC versus [90Y-DOTA]-TOC plus [177Lu-DOTA]-TOC in neuroendocrine cancers. J. Clin. Oncol. 30, 1100-1106 (2012).
2. Kwekkeboom, D. J. et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate: toxicity, efficacy, and survival. J. Clin. Oncol. 26, 2124-2130 (2008).
3. Imhof, A. et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J. Clin. Oncol. 29, 2416-2423 (2011).
4. Bushnell, D. L. Jr et al. 90Y-Edotreotide for metastatic carcinoid refractory to octreotide. J. Clin. Oncol. 28, 1652-1659 (2010).
5. Khan, S. et al. Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0, Tyr3]octreotate. J. Nucl. Med. 52, 1361-1368 (2011).
6. Raymond, E. et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med. 364, 501-513 (2011).
7. de Jong, M., Breeman, W. A., Valkema, R., Bernard, B. F. & Krenning, E. P. Combination radionuclide therapy using 177Lu-and 90Y-labeled somatostatin analogs. J. Nucl. Med. 46 (Suppl. 1), 13S-17S (2005). (Pubitemid 47619014)
8. O'Donoghue, J. A., Bardiès, M. & Wheldon, T. E. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J. Nucl. Med. 36, 1902-1909 (1995).
9. Kunikowska, J. et al. Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option? Eur. J. Nucl. Med. Mol. Imaging 38, 1788-1797 (2011).
10. De Kruijk, J. R., Leffers, P., Meerhoff, S., Rutten, J. & Twijnstra, A. Effectiveness of bed rest after mild traumatic brain injury: a randomised trial of no versus six days of bed rest. J. Neurol. Neurosurg. Psychiatry 73, 167-172 (2002).